Former FDA Commissioner Scott Gottlieb elected to Pfizer’s Board of Directors
pharmafile | June 28, 2019 | News story | Medical Communications | FDA, Pfizer, Scott Gottlieb, pharma
Dr Scott Gottlieb, who stepped down from his role as the 23rd Commissioner of the FDA earlier this year, has been elected to the Board of Directors at US pharmaceutical firm Pfizer, effective immediately.
Alongside this appointment, Dr Gottlieb was also appointed to the Board’s Regulatory and Compliance Committee and the Science and Technology Committee.
Following his departure from the US regulator, it was reported that Dr Gottlieb had returned to his venture capital roots, rejoining New Enterprise Associates as a Special Partner – the same company he served at for a decade between 2007 and 2017, at which point he left to join the FDA. He holds this role concurrently with his new appointment, as well as serving as a Resident Fellow of the American Enterprise Institute.
“We are fortunate to have Dr Gottlieb join Pfizer’s Board of Directors,” commented Pfizer Executive Chairman Ian Read. “Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.”
Dr Albert Bourla, the company’s Chief Executive Officer, also remarked: “We welcome Dr. Gottlieb to Pfizer’s Board of Directors. Through his work as a physician and his time at the FDA, Scott has continually demonstrated an understanding of both patients’ needs and the rapidly changing dynamics of biopharmaceutical research and development.”
Matt Fellows
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
